Current Price and Market Context
As of 21 Jul 2026, Alembic Pharmaceuticals Ltd. closed at ₹841.60, up from the previous close of ₹825.35. The stock traded within a range of ₹828.80 to ₹848.50 during the day, remaining well below its 52-week high of ₹1,064.70 but comfortably above the 52-week low of ₹635.30. Classified as a small-cap within the Pharmaceuticals & Biotechnology sector, Alembic’s market cap grade reflects its relatively modest size compared to larger industry peers.
Technical Trend Evolution
The stock’s technical trend has shifted from a sideways pattern to a mildly bearish one, signalling a subtle change in investor sentiment. This shift is corroborated by the daily moving averages, which currently indicate a mildly bearish outlook. The moving averages, often used to smooth out price data and identify trend direction, suggest that short-term price momentum is weakening.
MACD and Momentum Indicators
The Moving Average Convergence Divergence (MACD) indicator presents a dichotomy: the weekly MACD remains bullish, implying positive momentum in the short term, while the monthly MACD is bearish, signalling longer-term caution. This divergence suggests that while recent price action has been encouraging, underlying monthly trends may be signalling a potential slowdown or correction ahead.
RSI and Bollinger Bands Analysis
The Relative Strength Index (RSI) on both weekly and monthly timeframes currently shows no definitive signal, indicating neither overbought nor oversold conditions. This neutral RSI reading suggests that the stock is not presently exhibiting extreme momentum in either direction.
Bollinger Bands add further nuance: weekly bands are bullish, reflecting price strength and potential upward volatility, whereas monthly bands are mildly bearish, hinting at possible resistance or consolidation in the longer term. This mixed signal from Bollinger Bands aligns with the MACD’s conflicting weekly and monthly readings.
Additional Technical Indicators
The Know Sure Thing (KST) oscillator also reflects this duality, with a bullish weekly reading contrasting a bearish monthly stance. Meanwhile, Dow Theory analysis finds no clear weekly trend but identifies a mildly bullish monthly trend, suggesting that while short-term price action is uncertain, the broader market context may still favour the stock.
On-Balance Volume (OBV) shows no trend on the weekly scale but is bullish monthly, indicating that longer-term volume flows support price appreciation, a positive sign for investors looking beyond immediate fluctuations.
Patience pays off here! This Micro Cap from Fertilizers sector has delivered steady gains quarter after quarter. Now proudly part of our Reliable Performers list.
- - New Reliable Performer
- - Steady quarterly gains
- - Fertilizers consistency
Performance Relative to Sensex and Sector
Examining Alembic Pharmaceuticals’ returns relative to the Sensex reveals a mixed performance. Over the past week, the stock outperformed the Sensex with a 1.32% gain versus the benchmark’s 0.12%. The one-month return is particularly strong at 10.49%, significantly ahead of the Sensex’s 1.18% rise. However, year-to-date (YTD) performance shows a slight decline of 0.78%, though this is still better than the Sensex’s 8.81% fall.
Longer-term returns paint a more challenging picture. Over the past year, Alembic has declined by 18.28%, considerably underperforming the Sensex’s 4.95% drop. The three-year return of 17.98% slightly exceeds the Sensex’s 15.00%, but the five-year return of -10.43% lags far behind the Sensex’s robust 48.87% gain. Over a decade, Alembic’s 42.84% return is dwarfed by the Sensex’s 178.37%, underscoring the stock’s volatility and inconsistent long-term growth.
Mojo Score and Rating Update
MarketsMOJO’s latest assessment assigns Alembic Pharmaceuticals a Mojo Score of 45.0, categorising it as a Sell. This represents a downgrade from the previous Hold rating, effective from 20 Jul 2026. The downgrade reflects the deteriorating technical outlook and mixed fundamental signals, cautioning investors about the stock’s near-term prospects.
Investment Implications and Outlook
The technical indicators collectively suggest that Alembic Pharmaceuticals is at a crossroads. The bullish weekly MACD, Bollinger Bands, and KST indicate short-term momentum that could support further gains. However, the bearish monthly MACD, mildly bearish Bollinger Bands, and daily moving averages warn of potential headwinds ahead. The neutral RSI readings imply that the stock is not currently overextended, leaving room for either a rebound or further decline depending on market catalysts.
Investors should weigh these mixed signals carefully, considering the stock’s recent outperformance over the past month against its longer-term underperformance relative to the Sensex. The downgrade to a Sell rating by MarketsMOJO underscores the need for caution, particularly given the stock’s small-cap status and sector volatility.
Why settle for Alembic Pharmaceuticals Ltd.? SwitchER evaluates this Pharmaceuticals & Biotechnology small-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Conclusion
Alembic Pharmaceuticals Ltd. presents a technically complex profile with short-term bullish momentum tempered by longer-term bearish signals. The stock’s recent price gains and positive weekly indicators offer some optimism, but the downgrade to a Sell rating and mixed monthly trends counsel prudence. Investors should monitor key technical levels and broader market developments closely before committing fresh capital.
Given the stock’s small-cap nature and sector-specific risks, a cautious approach is advisable, favouring a wait-and-watch stance or exploring alternative opportunities within the Pharmaceuticals & Biotechnology space that demonstrate clearer technical and fundamental strength.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
